about
Aspirin resistance: current status and role of tailored therapyA shear gradient-activated microfluidic device for automated monitoring of whole blood haemostasis and platelet function.Low dose aspirin and pregnancy: how important is aspirin resistance?Aspirin resistance: an evaluation of current evidence and measurement methodsAspirin resistanceThe variability of platelet response to aspirin and clopidogrel: revisiting the Caprie, Cure, Credo, and Match trials.Aspirin and clopidogrel resistance: an emerging clinical entityAspirin resistance and its implications in clinical practiceThromboelastography: potential bedside tool to assess the effects of antiplatelet therapy?Evidence that pre-existent variability in platelet response to ADP accounts for 'clopidogrel resistance'Do the Behring Coagulation Timer and the Platelet Function Analyzer-100 identify the same patients as being aspirin non-responders?Clinical implications of aspirin resistanceState-of-the-Art: Hypo-responsiveness to oral antiplatelet therapy in patients with type 2 diabetes mellitus.A novel ultrasound-based method to evaluate hemostatic function of whole bloodPoint-of-care platelet reactivity determination with VerifyNow-P2Y12 following administration of clopidogrel or prasugrel: data from a real-world, clinical care inpatient setting.Novel methodology for assessment of prophylactic platelet transfusion therapy by measuring increased thrombus formation and thrombin generation.P2Y12 platelet receptors: importance in percutaneous coronary interventionDevelopment of a method to quantify platelet adhesion and aggregation under static conditionsEffects of recombinant human erythropoietin on platelet activation in acute myocardial infarction: results of a double-blind, placebo-controlled, randomized trial.Microfluidic assay of platelet deposition on collagen by perfusion of whole blood from healthy individuals taking aspirinUrinary 11-dehydro-thromboxane B₂ and 2,3-dinor-6-keto-prostaglandin-F₁α in healthy post-menopausal and pre-menopausal women receiving aspirin 100 mg.Aspirin and platelet adenosine diphosphate receptor antagonists in acute coronary syndromes and percutaneous coronary intervention: role in therapy and strategies to overcome resistance.Detection of clopidogrel hyporesponsiveness using a point-of-care assay and the impact of additional cilostazol administration after coronary stent implantation in diabetic patients.Assessment of spontaneous platelet aggregation using laser light scattering in healthy subjects: an attempt to standardize.Platelet volume indices are associated with systolic and diastolic cardiac dysfunction, and left ventricular hypertrophy.Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Intensified Antiplatelet Treatment Reduces Major Cardiac Events in Patients with Clopidogrel Low Response: A Meta-analysis of Randomized Controlled Trials.An Assay of Measuring Platelet Reactivity Using Monoclonal Antibody against Activated Platelet Glycoprotein IIb/IIIa in Patients Taking ClopidogrelProtocol for a systematic review of the diagnostic and prognostic utility of tests currently available for the detection of aspirin resistance in patients with established cardiovascular or cerebrovascular diseaseEffect of PSI-697, a novel P-selectin inhibitor, on platelet-monocyte aggregate formation in humans.Comparing of light transmittance aggregometry and modified thrombelastograph in predicting clinical outcomes in Chinese patients undergoing coronary stenting with clopidogrel.Brain injury secondary to carotid intervention.Aspirin and clopidogrel response variability: review of the published literatureHemorrhagic complications after prasugrel (Effient) therapy for vascular neurointerventional procedures.Mean platelet volume and prevalence of peripheral artery disease, the National Health and Nutrition Examination Survey, 1999-2004.Diabetes mellitus: a prothrombotic state implications for outcomes after coronary revascularizationAspirin resistance: disparities and clinical implications.Static platelet adhesion, flow cytometry and serum TXB2 levels for monitoring platelet inhibiting treatment with ASA and clopidogrel in coronary artery disease: a randomised cross-over studyMean platelet volume reproducibility and association with platelet activity and anti-platelet therapy.Monitoring oral antiplatelet therapy: is it justified?
P2860
Q26851367-93EBBF04-5976-4298-8287-F2188715DD6CQ27339266-CC3305F6-BFB2-4406-9D23-CE82DBDB93A4Q28068597-DEC46CB0-7CEA-467C-AAB6-610469312491Q28183220-8FDBCA10-05AA-45C1-8A60-B7E4DB074C6CQ28187611-2F49308A-116F-43AE-9BAF-F296DD37E95CQ28192919-8319AAAF-83F5-4B70-A105-79CBE4EE2C94Q28194021-DAD5C4B2-08C5-4727-AB70-8506E3DFEA35Q28194069-246E96F4-D211-4833-8402-66873DC4FF2AQ28200486-121597CF-640B-46F6-AD18-2B173339AE82Q28200552-FE81254C-E540-407D-940A-8A14355C1059Q28218887-788F1800-C4BB-4F60-AF67-2D94A50F75B6Q28221576-132CD434-6B93-4689-80EE-AA3311815A28Q30373414-47028E18-6EC6-4569-83C4-9605AB2700FFQ30433609-47FF6957-EF4D-4B91-8FA7-F879FCB4D410Q30877943-DE425E84-09F1-433D-A98E-1C70D192FE79Q33373629-A980BE25-7AEB-4AD3-8B1E-7E51F9D4445FQ33655109-B54BA712-02C2-4DAE-9C7B-3952766B54FDQ33678453-551843F3-6DD1-4C2C-8D9D-00538CCEE8BDQ33726150-D7D4EC05-E682-43A7-AEA7-80A7DA370373Q33992761-CA84AE70-1DA0-4DB7-9885-7F83EF28687AQ34152333-056A52CC-1EBB-46AD-8AC7-5CCB1E540CFDQ34771381-DDFB4143-F2B7-44E7-B50C-14034F156B35Q35033557-E215B807-2409-4959-B3FA-650FC4CE20C4Q35128798-EEA8ECC4-8F78-46A5-B920-FE77B30B8020Q35664650-F58D3AC0-929E-4462-8544-BCB130396FECQ35752608-D10FCA65-FCEE-4EEC-BF3F-66FBE6DD4509Q35985453-44C1B308-688D-415F-8F80-3E42065D12B3Q36087455-DE4650FB-E404-4E8D-A294-434BC752C3FBQ36693620-758AF97F-FB66-4202-A296-2F32A634277DQ36701850-667F9CCE-83E9-42B9-AB14-D86DF507F363Q36804776-838E9296-28CE-48E5-ACD6-0A2D434F17A4Q36815152-D0DEC05B-7257-4627-B1BC-84CFF3C0855DQ36932221-3DC20EBB-7E38-4716-88A1-85985205AFD5Q36939417-AF04E7DF-9777-4AA7-AE6F-657788AC638DQ37084956-35358B37-72C8-4AA5-B44C-F3A019F51BC8Q37167506-3EF382CF-78FF-4DED-B40E-5D36C39F0630Q37227512-01B48973-06F5-4F71-8078-46CCC3120EEFQ37234897-C01EB664-C589-4D10-9AC9-EB93465AD0CDQ37257153-9BEFB039-6285-459E-90F4-DD2DCF6F9430Q37362783-B5230198-AB0A-4DA9-A1F6-31D40DE4CEF7
P2860
description
2004 nî lūn-bûn
@nan
2004 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Platelet function testing in cardiovascular diseases
@ast
Platelet function testing in cardiovascular diseases
@en
Platelet function testing in cardiovascular diseases
@nl
type
label
Platelet function testing in cardiovascular diseases
@ast
Platelet function testing in cardiovascular diseases
@en
Platelet function testing in cardiovascular diseases
@nl
prefLabel
Platelet function testing in cardiovascular diseases
@ast
Platelet function testing in cardiovascular diseases
@en
Platelet function testing in cardiovascular diseases
@nl
P3181
P1433
P1476
Platelet function testing in cardiovascular diseases
@en
P2093
Alan D Michelson
P304
P3181
P356
10.1161/01.CIR.0000147228.29325.F9
P407
P577
2004-11-09T00:00:00Z